What insurance policy changes affect HCPCS J8612?

There are 6 tracked policy changes affecting HCPCS J8612, including updates from Aetna, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J8612?

Payers that have issued tracked updates for HCPCS J8612 include: Aetna, Independence Blue Cross.

How do I get notified when HCPCS J8612 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J8612. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J8612?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J8612 Insurance Policy Changes

HCPCS J8612 is officially defined as "Methotrexate (xatmep), oral, 2.5 mg." HCPCS J8612 is referenced in 6 tracked payer policy changes from Aetna and Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J8612 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact
Belimumab (Benlysta) (CPB 0818, reviewed 2026-06-10)
Aetna·Effective Jun 10, 2026
Aetna has updated its Belimumab (Benlysta) clinical policy effective June 10, 2026, establishing mandatory precertification requirements, specific approval criteria for SLE and lupus nephritis treatment, specialist prescriber requirements, and clear exclusions for CNS lupus and biologic combination therapy. Billing teams must implement precertification workflows and ensure claims meet the defined clinical criteria before submission.
High impact
Anifrolumab-fnia (Saphnelo) (CPB 0997, reviewed 2026-06-05)
Aetna·Effective Jun 5, 2026
Aetna has issued a new clinical policy (CPB 0997, effective 2026-06-05) establishing coverage criteria for anifrolumab-fnia (Saphnelo) for moderate to severe systemic lupus erythematosus (SLE) in adults. The policy requires precertification for all Aetna participating providers, mandatory rheumatology consultation, specific autoantibody confirmation, and concurrent standard SLE therapy. Coverage explicitly excludes severe active lupus nephritis, severe CNS lupus, and concurrent biologic use.
High impact
Temozolomide (Temodar) Injection (CPB 0876, reviewed 2026-06-03)
Aetna·Effective Jun 3, 2026
Aetna issued a comprehensive clinical policy bulletin for Temozolomide (Temodar) injection establishing covered indications for 13 specific cancer types and designating all other uses as experimental/investigational. This 1-day-old policy defines medical necessity criteria, dosing guidelines, and billing requirements for J9328 claims. Practices must verify patient diagnoses against the covered indication list before billing to avoid denials.
High impact
Levoleucovorin (Khapzory) (CPB 0889, reviewed 2025-12-04)
Aetna·Effective Dec 4, 2025
Aetna is implementing a cost-containment policy for Levoleucovorin (Khapzory) that requires precertification for all commercial medical plan members. Khapzory is now considered medically necessary only when leucovorin is unavailable or when members have a contraindication, intolerance, or ineffective response to generic levoleucovorin. Generic levoleucovorin is now the preferred first-line option for all three approved indications.
Medium impact
Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) (CPB 0634, reviewed 2026-09-25)
Aetna·Identified Oct 6, 2026
This is a policy review of Aetna's CPB 0634 for non-myeloablative hematopoietic cell transplantation (mini-allograft). The policy was reviewed on 2026-09-25 but the document provided contains the full policy text without identifying specific changes from a prior version. The policy establishes medical necessity criteria for mini-allograft procedures in specified hematologic malignancies and bone marrow failure syndromes, while designating other indications as experimental/investigational.
Low impact
MA11.010d, Abortion
Independence Blue Cross·Identified Jun 19, 2026
Independence Blue Cross reissued MA11.010d (Abortion) on 04/01/2026 with no substantive changes to coverage criteria. Two methotrexate HCPCS codes (J8611, J8612) were added to the policy's medication code list. The policy continues to cover abortion only for rape/incest or life-endangering physical conditions, with required medical documentation.

All billing codes J3590 C9399 J3490 99213 99214 99212

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

Belimumab (Benlysta) (CPB 0818, reviewed 2026-06-10)

Anifrolumab-fnia (Saphnelo) (CPB 0997, reviewed 2026-06-05)

Temozolomide (Temodar) Injection (CPB 0876, reviewed 2026-06-03)

Levoleucovorin (Khapzory) (CPB 0889, reviewed 2025-12-04)

Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) (CPB 0634, reviewed 2026-09-25)

MA11.010d, Abortion